Related Experiment Video
Updated: Jul 15, 2026
11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
7.8K
Proteomic Changes Associated With Endogenous FBXW7 Mutations in Moderately Differentiated Endometrial Cancer Cells
Mary Ellen Urick1, Suresh Kumar Chalapareddy1, Eun-Jeong Yu1
1Reproductive Cancer Genetics Section, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Cancer Medicine
|March 15, 2025
Summary
Endometrial cancer (EC) is linked to FBXW7 gene mutations. This study reveals proteomic changes, including elevated galectin-3 and TROP2 levels, offering potential therapeutic targets for EC.
Area of Science:
- Oncology
- Proteomics
- Cancer Genomics
Background:
- Endometrial cancer (EC) is a significant health concern for women in the US.
- The FBXW7 tumor suppressor gene is frequently altered in EC.
- FBXW7 mutations impact protein degradation pathways.
Purpose of the Study:
- To investigate the proteomic and phosphoproteomic alterations in EC cells with endogenous FBXW7 mutations.
- To identify key proteins affected by FBXW7 loss-of-function.
Main Methods:
- Quantitative LC-MS/MS was employed to analyze proteomes and phosphoproteomes.
- Two FBXW7-mutated EC cell lines were compared to isogenic controls.
- Western blotting validated key protein expression changes.
Main Results:
- 397 proteins and/or phosphoproteins showed significant differential expression.
- Elevated levels of TROP2, galectin-3, ASS1, and PLCG2 were observed in mutated cells.
- These findings were confirmed through orthogonal validation.
Conclusions:
- FBXW7 mutations in EC lead to distinct proteomic and phosphoproteomic profiles.
- Increased galectin-3 and TROP2 present potential therapeutic targets for EC treatment.
- This research provides insights into the molecular consequences of FBXW7 alterations in EC.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...